Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Cardiology

Long-Term Care and Monitoring

At a Glance

Long-term atherosclerosis care requires regular cholesterol testing, consistent use of prescribed medicines, heart-healthy habits, and prompt attention to serious side effects. After a stent, never stop clot-preventing antiplatelet medicine without the cardiology team’s guidance.

Atherosclerosis is a lifelong condition that requires an active partnership with your medical team. Success is not measured by a single procedure or a “normal” lab result, but by your ability to maintain heart-healthy habits and stay consistent with medications that protect your arteries from future events [1][2].

Monitoring Your Progress

After starting or changing a lipid-lowering medication (like a statin), your doctor will order a lipid panel—a blood test that measures your cholesterol and triglycerides.

  • Initial Check: Standard guidelines recommend your first follow-up lipid panel 4 to 12 weeks after starting a new medication to see how well it is working and to ensure you are tolerating the dose [3][4].
  • Long-Term Follow-Up: Once your cholesterol is stable and at your goal, testing may happen every 3 to 12 months, depending on your specific risk and whether other health changes occur [3][5].
  • Checking Other Markers: If you are on a statin, your doctor may periodically check your blood sugar or HbA1c based on your baseline risk [6][7]. If you take bempedoic acid, they will also monitor your uric acid levels to watch for a risk of gout [8][9].

The Lifeline: Medication Adherence

Taking your medications exactly as prescribed is the single most important thing you can do to prevent a heart attack or stroke. This is especially true for antiplatelet therapy (like aspirin and a P2Y12 inhibitor such as clopidogrel) after a stent procedure.

  • Dual Antiplatelet Therapy (DAPT) Window: After a stent or heart attack, DAPT duration is individualized based on bleeding and ischemic risks, stent type, and procedural features [10]. While 6 to 12 months is common, some courses are shorter and some patients need longer therapy [11]. The risk of a blood clot forming inside a new stent (stent thrombosis) is particularly high in the first days to weeks.
  • Never Stop Without Asking: Even if you have a planned surgery or dental work, do not stop your antiplatelet medicines without explicitly speaking to the treating cardiology team. They must coordinate with your procedural clinician to make an individualized plan; antiplatelet “bridging” is not routine, and many dental procedures do not require interruption [12][13].

Managing Side Effects Safely

All medications have potential side effects, but most can be managed without stopping the drug entirely.

Statin Muscle Symptoms

If you experience new muscle aches or weakness (myalgia), do not just stop the pill.

  • What to Look For: Statin-related pain can affect both sides of the body, be unilateral, be delayed, or be caused by interactions or another condition [14][15]. Discuss new symptoms with your clinician, who may measure your CK (creatine kinase) levels when indicated.
  • When it’s Urgent: Contact your doctor immediately if you have severe muscle weakness, extreme fatigue, or dark, tea-colored urine, which could indicate a rare but serious condition called rhabdomyolysis [16][17].

Bleeding and Bruising

On antiplatelet therapy, you will likely bruise more easily and bleed longer from small cuts.

  • Report to Doctor: Frequent nosebleeds, or bleeding that doesn’t stop after 10 minutes of pressure.
  • Urgent Bleeding: Seek immediate emergency care if you experience:
    • Black or bloody stools
    • Vomiting or coughing up blood
    • Severe persistent bleeding
    • Sudden severe headache or neurologic change
    • (Do not stop your antiplatelet medicine on your own while seeking emergency care).

Your Routine Follow-Up Checklist

At your regular check-ups, come prepared to discuss the following with your care team [1][18]:

  1. Symptoms: Have you had any new chest pain, shortness of breath, or leg pain while walking?
  2. Blood Pressure: Share any readings you have taken at home.
  3. Adherence: Have you missed any doses? Be honest—your doctor can help find solutions if cost or side effects are barriers [19].
  4. Lifestyle: Discuss any challenges with diet, exercise, or quitting smoking [2].
  5. Lab Results: Review your LDL-C, kidney function, and blood sugar trends.

Staying on top of these routine checks ensures that your treatment plan evolves as you do, keeping your risk as low as possible over the long term [2][20].

Common questions in this guide

When should I repeat my cholesterol test after starting a statin?
A lipid panel is usually checked 4 to 12 weeks after starting or changing a cholesterol-lowering medicine. Once your levels are stable, testing may be done every 3 to 12 months, depending on your risk and any health changes.
How long do I need aspirin and clopidogrel after a stent?
The length of dual antiplatelet treatment after a stent or heart attack is individualized. Six to 12 months is common, but your cardiology team may recommend a shorter or longer course based on clotting and bleeding risks, the stent, and the procedure.
Can I stop my antiplatelet medicine before dental work or surgery?
Do not stop aspirin or a P2Y12 medicine such as clopidogrel without speaking with the cardiology team that manages your stent or heart condition. The cardiology and procedural teams should make the plan together, and many dental procedures do not require stopping these medicines.
What should I do if I develop muscle pain while taking a statin?
Tell your clinician about new muscle aches or weakness instead of stopping the statin on your own; they may check creatine kinase or look for another cause. Seek urgent medical help for severe weakness, extreme fatigue, or dark, tea-colored urine.
What bleeding symptoms are an emergency on antiplatelet treatment?
Easy bruising and longer bleeding from small cuts can occur, but contact your doctor about frequent nosebleeds or bleeding that does not stop after 10 minutes of pressure. Seek emergency care for black or bloody stools, vomiting or coughing blood, severe persistent bleeding, or sudden changes in speech, movement, or alertness, and do not stop the medicine on your own while seeking care.
What happens if my LDL cholesterol stays above my target?
If your LDL cholesterol remains above the target your clinician set, ask what adjustment is needed rather than changing the dose yourself. Your team can review your results, medication use, side effects, and whether another cholesterol-lowering treatment is appropriate.
Why is uric acid checked when I take bempedoic acid?
Bempedoic acid can raise uric acid, so your clinician may monitor this level, especially if you have a history of gout. Ask what result would require a change in your care and report possible gout symptoms promptly.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the exact date I can safely stop one of my 'blood thinner' medications after my stent procedure?
  2. 2.If I need dental work or a minor surgery, should I stop my aspirin or P2Y12 inhibitor, and who should I call to confirm?
  3. 3.How often will you be checking my HbA1c or blood sugar while I am on a high-intensity statin?
  4. 4.Since I am taking bempedoic acid, what uric acid level should we be concerned about?
  5. 5.If my LDL-C does not reach the target of <55 mg/dL on my current dose, what is the next step in my treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.

    Chao TH, Lin TH, Cheng CI, et al.

    Acta Cardiologica Sinica 2024; (40(5)):479-543 doi:10.6515/ACS.202409_40(5).20240724A.

    PMID: 39308649
  2. 2

    2025 Egyptian guidelines for the management of dyslipidemia.

    Reda A, Taha HS, Badran HM, et al.

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2026; (78(1)):6 doi:10.1186/s43044-026-00716-9.

    PMID: 41557222
  3. 3

    Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

    Deshotels MR, Virani SS, Ballantyne CM

    Current cardiology reports 2021; (23(9)):116 doi:10.1007/s11886-021-01545-9.

    PMID: 34269897
  4. 4

    Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System.

    Jia X, Al Rifai M, Ramsey DJ, et al.

    The American journal of medicine 2019; (132(9)):e693-e700 doi:10.1016/j.amjmed.2019.04.002.

    PMID: 31103643
  5. 5

    The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project.

    Laufs U, Catapano AL, De Caterina R, et al.

    Vascular pharmacology 2023; (148()):107141 doi:10.1016/j.vph.2023.107141.

    PMID: 36626974
  6. 6

    Statin Use and Hyperglycemia: Do Statins Cause Diabetes?

    Bredefeld CL, Choi P, Cullen T, et al.

    Current atherosclerosis reports 2024; (27(1)):18 doi:10.1007/s11883-024-01266-8.

    PMID: 39699704
  7. 7

    Diabetogenic Action of Statins: Mechanisms.

    Carmena R, Betteridge DJ

    Current atherosclerosis reports 2019; (21(6)):23 doi:10.1007/s11883-019-0780-z.

    PMID: 31037345
  8. 8

    Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.

    Banach M, Duell PB, Gotto AM, et al.

    JAMA cardiology 2020; (5(10)):1124-1135 doi:10.1001/jamacardio.2020.2314.

    PMID: 32609313
  9. 9

    Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion.

    Hiremath J, Mohan JC, Hazra P, et al.

    Cureus 2023; (15(2)):e35395 doi:10.7759/cureus.35395.

    PMID: 36987470
  10. 10

    Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, and Adverse Outcomes After Successful Percutaneous Coronary Intervention.

    Redfors B, Kirtane AJ, Liu M, et al.

    JACC. Cardiovascular interventions 2022; (15(8)):797-806 doi:10.1016/j.jcin.2022.01.300.

    PMID: 35450679
  11. 11

    Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.

    Kamran H, Jneid H, Kayani WT, et al.

    JAMA 2021; (325(15)):1545-1555 doi:10.1001/jama.2021.0716.

    PMID: 33877270
  12. 12

    Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery.

    Banerjee S, Angiolillo DJ, Boden WE, et al.

    Journal of the American College of Cardiology 2017; (69(14)):1861-1870 doi:10.1016/j.jacc.2017.02.012.

    PMID: 28385315
  13. 13

    The Use of Cangrelor as Bridge Antiplatelet Therapy in a Patient with Recent Percutaneous Coronary Intervention for Acute Coronary Syndrome, Who Developed Esophageal Perforation After Transesophageal Echocardiography.

    Guliyeva U, Karaüzüm K, Çam İ, et al.

    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2024; (52(5)):352-356 doi:10.5543/tkda.2023.50000.

    PMID: 38982817
  14. 14

    Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical Prevention, Evaluation, and Management Algorithm.

    Epelde F

    Medicina (Kaunas, Lithuania) 2026; (62(6)) doi:10.3390/medicina62061134.

    PMID: 42356146
  15. 15

    Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy.

    Vinci P, Panizon E, Tosoni LM, et al.

    International journal of molecular sciences 2021; (22(21)) doi:10.3390/ijms222111687.

    PMID: 34769118
  16. 16

    Statin-associated side effects in patients attending a lipid clinic: evidence from a 6-year study.

    Barkas F, Adamidis P, Koutsogianni AD, et al.

    Archives of medical sciences. Atherosclerotic diseases 2021; (6()):e182-e187 doi:10.5114/amsad.2021.111313.

    PMID: 36161219
  17. 17

    Muscle Damage Due to Fusidic Acid-Statin Interaction: Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports.

    Bataillard M, Beyens MN, Mounier G, et al.

    American journal of therapeutics 2019; (26(3)):e375-e379 doi:10.1097/MJT.0000000000000679.

    PMID: 29189310
  18. 18

    Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016.

    Romanelli RJ, Ito MK, Karalis DG, et al.

    Journal of clinical lipidology 2020; (14(3)):305-314 doi:10.1016/j.jacl.2020.03.006.

    PMID: 32362513
  19. 19

    Adherence to dual antiplatelet therapy after coronary stenting: A study conducted at two Vietnamese hospitals.

    Tien Hoang A, Quynh Nhu Tran T, Phuong Duy Le C, Ha Vo T

    Journal of cardiovascular and thoracic research 2021; (13(4)):330-335 doi:10.34172/jcvtr.2021.52.

    PMID: 35047138
  20. 20

    Effect of Lipid-Testing Interval on Stoke Risk among Newly Diagnosed Dyslipidemia Patients Initiated on Statins.

    Ko A, Choi S, Chang J, Park SM

    Journal of clinical medicine 2019; (8(5)) doi:10.3390/jcm8050742.

    PMID: 31137637

This page is for informational purposes only and does not constitute medical advice. Ask your cardiology team before changing a medicine, stopping antiplatelet therapy, or deciding how to respond to side effects.

Get notified when new evidence is published on atherosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.